Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Anti-CD27 agonist antibody varlilumab in combination with nivolumab for recurrent glioblastoma (rGBM): Phase 2 clinical trial results
    Meeting Abstract

    Reardon, D.; Kaley, T.; Iwamoto, F.; Baehring, J.; Subramaniam, D.; Rawls, T.; He, Y.; Keler, T.; Yellin, M.
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • Interim results of a phase II multicenter study of the conditionally replicative oncolytic adenovirus DNX-2401 with pembrolizumab (Keytruda) for recurrent glioblastoma: Captive study (Keynote-192)
    Meeting Abstract

    Zadeh, G.; Lang, F.; Daras, M.; Cloughesy, T.; Colman, H.; Ong, S.; Ramakrishna, R.; Vogelbaum, M.; Groves, M.; Nassiri, F.; more...
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab, durva) + bevacizumab (BEV) in bev-naive patients with recurrent glioblastoma (GBM)
    Meeting Abstract

    Reardon, D.; Kaley, T.; Dietrich, J.; Clarke, J.; Dunn, G.; Lim, M.; Cloughesy, T.; Gan, H.; Park, A.; Schwarzenberger, P.; more...
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM
    Meeting Abstract

    Alexander, B.; Supko, J.; Agar, N.; Ahluwalia, M.; Desai, A.; Dietrich, J.; Kaley, T.; Peereboom, D.; Takebe, N.; Desideri, S.; more...
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • Safety and preliminary activity of PT2385, a first-in-class HIF2-alpha inhibitor, planned interim analysis of an open label, single-arm phase II study in patients with recurrent glioblastoma
    Meeting Abstract

    Strowd, R.; Ellingson, B.; Wen, P.; Ahluwalia, M.; Piotrowski, A.; Desai, A.; Clarke, J.; Lieberman, F.; Desideri, S.; Nabors, L. B.; more...
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • Neoadjuvant anti-PD-1 immunotherapy promotes intratumoral and systemic immune responses in recurrent glioblastoma: An Ivy Consortium trial
    Meeting Abstract

    Prins, R.; Mochizuki, A.; Orpilla, J.; Lee, A.; Davidson, T.; Gaffey, S.; Sanders, C.; Rytlewski, J.; Ellingson, B.; Li, G.; more...
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • Global longitudinal strain in the SAFE-HEaRT study (Cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function)
    Meeting Abstract

    Barac, A.; Lynce, F.; Medvedofsky, D. A.; Geng, X.; Dang, C.; Yu, A.; Tan, M.; Isaacs, C.; Swain, S. M.; Asch, F. M.
    European Heart Journal (2018)

    Fulltext@MSK | Save
  • Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
    Meeting Abstract

    Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Cowey, C. L.; Lao, C.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Meeting Abstract

    Javle, M.; Kelley, R. K.; Roychowdhury, S.; Weiss, K. H.; Abou-Alfa, G. K.; Macarulla, T.; Sadeghi, S.; Waldschmidt, D.; Zhu, A. X.; Goyal, L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Rini, B. I.; Huseni, M.; Atkins, M. B.; McDermott, D. F.; Powles, T. B.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; Fan, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save